{"id":"nalmefene-hcl-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Withdrawal symptoms (in opioid-dependent patients)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nalmefene competitively antagonizes mu, delta, and kappa opioid receptors, preventing opioid agonists from binding and exerting their effects. It has a longer duration of action and higher receptor binding affinity compared to naloxone, making it suitable for both acute opioid overdose reversal and longer-term opioid dependence management. The drug rapidly displaces opioids from receptor sites, reversing respiratory depression and other opioid effects.","oneSentence":"Nalmefene is a competitive opioid receptor antagonist that blocks the effects of opioids by binding to opioid receptors with high affinity and specificity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:41.299Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid overdose reversal"},{"name":"Opioid dependence management"}]},"trialDetails":[{"nctId":"NCT04713358","phase":"PHASE4","title":"Effect of Nalmefene on the Quality of Resuscitation in Patients Under General Anesthesia","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2021-09-24","conditions":"Resuscitation","enrollment":542},{"nctId":"NCT06719986","phase":"PHASE1","title":"Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2022-10-03","conditions":"Opioid Overdose","enrollment":24},{"nctId":"NCT06198686","phase":"PHASE1","title":"An Evaluation of The Absolute Bioavailability of TH104","status":"COMPLETED","sponsor":"Tharimmune Inc","startDate":"2024-01-26","conditions":"Healthy","enrollment":20},{"nctId":"NCT06408714","phase":"PHASE3","title":"Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2024-08-26","conditions":"Opioid Overdose, Opiate Overdose","enrollment":""},{"nctId":"NCT05338632","phase":"PHASE1","title":"Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2022-06-24","conditions":"Opioid Induced Respiratory Depression, Chronic Opioid Use","enrollment":24},{"nctId":"NCT04759768","phase":"PHASE1","title":"Pharmacokinetic Evaluation of Intranasal Nalmefene","status":"COMPLETED","sponsor":"Opiant Pharmaceuticals Inc","startDate":"2021-02-08","conditions":"Pharmacokinetics","enrollment":68},{"nctId":"NCT05808881","phase":"PHASE4","title":"Clinical Outcomes From Nalmefene","status":"WITHDRAWN","sponsor":"Purdue Pharma LP","startDate":"2023-06","conditions":"Opioid Overdose","enrollment":""},{"nctId":"NCT03096730","phase":"NA","title":"Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative Hyperalgesia","status":"COMPLETED","sponsor":"Tianjin Medical University General Hospital","startDate":"2017-02-06","conditions":"Pain, Anesthesia","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nalmefene IV","Nalmefene","Nalmefene hydrochloride","Nalmefene HCl"],"phase":"marketed","status":"active","brandName":"Nalmefene HCl injection","genericName":"Nalmefene HCl injection","companyName":"Leiden University Medical Center","companyId":"leiden-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nalmefene is a competitive opioid receptor antagonist that blocks the effects of opioids by binding to opioid receptors in the central nervous system. Used for Opioid overdose reversal, Opioid dependence management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}